Celgene Corporation (CELG) Release: At American Society of Clinical Oncology, Oral Presentation from Intergroupe Francophone Du Myelome (IFM) of Phase III Study (IFM 2005 02) Evaluating Continuous REVLIMID® in Patients with Multiple Myeloma Following Autologous Stem Cell Transplant
6/7/2010 5:52:20 PM
BOUDRY, Switzerland--(BUSINESS WIRE)--Celgene International Sàrl (NASDAQ: CELG) today announced that data from an Intergroupe Francophone du Myelome clinical study under the sponsorship of the University Hospital of Toulouse were presented at the American Society of Clinical Oncology. Results of the study (IFM 2005 02) demonstrated that patients with multiple myeloma receiving continuous lenalidomide (REVLIMID) following a first-line autologous stem cell transplant (ASCT) had a 68% 3-year progression-free survival rate compared to 34% (HR=0.46, p<0.0000001) for patients that received placebo following ASCT. This translated to a 54% reduction in risk of disease progression for patients receiving continuous lenalidomide following ASCT.
comments powered by